

# Chiara Cattaneo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7196172/publications.pdf>

Version: 2024-02-01

47  
papers

2,521  
citations

218592

26  
h-index

223716

46  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4019  
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
2	When Viruses Meet Fungi: Tackling the Enemies in Hematology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
3	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
4	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. <i>Blood Advances</i> , 2022, 6, 5811-5820.	2.5	2
5	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
6	Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time. <i>Leukemia</i> , 2021, 35, 632-634.	3.3	3
7	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	2.0	4
8	Reply to COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 1939-1939.	2.0	1
9	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. <i>Blood</i> , 2021, 138, 1705-1720.	0.6	10
10	Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-GRADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. <i>Cancer Medicine</i> , 2021, 10, 5859-5865.	1.3	22
11	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
12	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. <i>Blood Cancer Journal</i> , 2021, 11, 151.	2.8	32
13	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
14	Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. <i>Cancer</i> , 2020, 126, 5069-5076.	2.0	69
15	Isavuconazole: Animal Data and Clinical Data. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 209.	1.5	7
16	Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-2B study). <i>Mycoses</i> , 2020, 63, 1094-1100.	1.8	6
17	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
18	Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. <i>American Journal of Hematology</i> , 2020, 95, 759-765.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Bloodstream infections caused by <i>Escherichia coli</i> in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. <i>PLoS ONE</i> , 2019, 14, e0224465.	1.1	27
20	Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome. <i>Leukemia and Lymphoma</i> , 2019, 60, 3044-3050.	0.6	17
21	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
22	HIV AND LYMPHOMA: FROM EPIDEMIOLOGY TO CLINICAL MANAGEMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019004.	0.5	47
23	â€œReal-lifeâ€™ analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	1.3	11
24	Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. <i>HemaSphere</i> , 2019, 3, e320.	1.2	8
25	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	0.8	10
26	Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. <i>Annals of Hematology</i> , 2018, 97, 1717-1726.	0.8	72
27	Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. <i>Hematological Oncology</i> , 2017, 35, 828-834.	0.8	36
28	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	2.8	98
29	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	2.9	103
30	Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel). <i>Annals of Hematology</i> , 2016, 95, 1955-1963.	0.8	19
31	Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. <i>American Journal of Hematology</i> , 2016, 91, 1076-1081.	2.0	115
32	Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience. <i>Leukemia and Lymphoma</i> , 2015, 56, 267-269.	0.6	35
33	Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections. <i>Mycoses</i> , 2015, 58, 362-367.	1.8	29
34	Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. <i>Clinical Microbiology and Infection</i> , 2015, 21, 337-343.	2.8	172
35	Relapsing bloodstream infections during treatment of acute leukemia. <i>Annals of Hematology</i> , 2014, 93, 785-790.	0.8	19
36	<i>Nocardia</i> spp infections among hematological patients: results of a retrospective multicenter study. <i>International Journal of Infectious Diseases</i> , 2013, 17, e610-e614.	1.5	39

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. <i>Clinical Infectious Diseases</i> , 2012, 55, 1515-1521.	2.9	77
38	A prospective survey of febrile events in hematological malignancies. <i>Annals of Hematology</i> , 2012, 91, 767-774.	0.8	48
39	<i>P. aeruginosa</i> bloodstream infections among hematological patients: an old or new question?. <i>Annals of Hematology</i> , 2012, 91, 1299-1304.	0.8	73
40	The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. <i>Haematologica</i> , 2011, 96, 1366-1370.	1.7	56
41	Multidrug resistant <i>Pseudomonas aeruginosa</i> bloodstream infection in adult patients with hematologic malignancies. <i>Haematologica</i> , 2011, 96, e1-e3.	1.7	67
42	A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2140-2145.	1.3	28
43	Recent increase in enterococci, viridans streptococci, <i>Pseudomonas</i> spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 324-332.	1.5	37
44	Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant <i>Escherichia coli</i> among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 721-728.	1.3	124
45	Usefulness of the MSG/IFCC/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. <i>Annals of Hematology</i> , 2007, 86, 205-210.	0.8	28
46	Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. <i>Leukemia and Lymphoma</i> , 2006, 47, 1013-1017.	0.6	124
47	Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 77-81.	0.6	50